KIT and digestive system neoplasm: Major advances were made in the treatment of chronic myeloid leukaemias and gastrointestinal tumours by using drugs that directly inhibit the pathways deregulated by the BCL2-ABL fusion gene and c-KIT mutations (Hochhaus, 2004).